EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PW Medtech Group's Enterprise Value is €57.06 Mil.
PW Medtech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €16.42 Mil. Therefore, PW Medtech Group's EV-to-FCF for today is 3.48.
The historical rank and industry rank for PW Medtech Group's EV-to-FCF or its related term are showing as below:
FRA:PWE'
s EV-to-FCF Range Over the Past 10 Years
Min: -490.86 Med: -4.1 Max: 69.81
Current: 3.45
During the past 13 years, the highest EV-to-FCF of PW Medtech Group was 69.81. The lowest was -490.86. And the median was -4.10.
FRA:PWE's EV-to-FCF is ranked better than 95.44% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.54
vs FRA:PWE: 3.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PW Medtech Group's PE Ratio (TTM) for today is calculated as:
PW Medtech Group's share price for today is €0.105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PW Medtech Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PW Medtech Group EV-to-FCF Related Terms
PW Medtech Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, PW Medtech Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's EV-to-FCF falls into.
PW Medtech Group's current Enterprise Value is €57.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PW Medtech Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €16.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group (FRA:PWE) has a EV-to-FCF of 3.48 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PW Medtech Group and its competitors. According to the industry distribution chart, PW Medtech Group ranks #19 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 4.6%.
Is PW Medtech Group's EV-to-FCF too high?
PW Medtech Group's current EV-to-FCF is 3.48. The Medical Devices & Instruments industry median EV-to-FCF is 23.54. PW Medtech Group's value of 3.48 is 85.2% below this industry median. Based on the distribution chart, PW Medtech Group ranks #19 out of 417 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PW Medtech Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #19 out of 417 companies for EV-to-FCF. This places PW Medtech Group in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.54. PW Medtech Group's value of 3.48 is 85.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.54, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current EV-to-FCF of 3.48 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current EV-to-FCF is 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current EV-to-FCF of 3.48. The stock's GF Value™ is €0.12, compared to a current price of €0.11 — trading 12.5% below its estimated fair value. The current EV-to-FCF is 3.48 and 85.2% below the Medical Devices & Instruments industry median of 23.54. PW Medtech Group's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current EV-to-FCF is 3.48 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 12.5% below its estimated GF Value™ of €0.12.
Key valuation signals for FRA:PWE:
EV-to-FCF: 3.48
GF Value™: €0.12 vs. price of €0.11 (12.5% below fair value)
Industry Position: 85.2% below the Medical Devices & Instruments median (#19 of 417)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
84GF Score
Get the complete analysis for FRA:PWE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
